Format

Send to

Choose Destination
Contraception. 2018 May;97(5):422-427. doi: 10.1016/j.contraception.2018.01.012. Epub 2018 Feb 2.

Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Author information

1
Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR. Electronic address: jensenje@ohsu.edu.
2
Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR.
3
Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
4
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA.
5
Pennsylvania Clinical Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania School of Medicine, Philadelphia, PA.
6
Reproductive Medicine Research, Department of Obstetrics & Gynecology, University of Cincinnati College of Medicine, Cincinnati, OH.
7
Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD.
8
Department of Obstetrics & Gynecology, Columbia University College of Physicians and Surgeons, New York, NY.
9
Department of Obstetrics & Gynecology, New York University School of Medicine, New York, NY.
10
Center for Biomedical Research, Population Council, New York, NY.
11
Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD.

Abstract

BACKGROUND:

As part of a program to develop a novel estradiol-releasing contraceptive vaginal ring (CVR), we evaluated the pharmacokinetic (PK) profile of CVRs releasing segesterone acetate (Nestorone® (NES)) combined with one of three different estradiol (E2) doses.

STUDY DESIGN:

A prospective, double-blind, randomized, multi-centered study to evaluate a 90-day CVR releasing NES [200mcg/day] plus E2, either 10mcg/day, 20mcg/day, or 40mcg/day in healthy reproductive-age women with regular cycles. Participants provided blood samples twice weekly for NES and E2 levels during the first 60 days (ring 1) and the last 30 days (ring 2) of use. A subset underwent formal PK assessments at ring initiation, ring exchange (limited PK), and study completion.

RESULTS:

The main study enrolled 197 women; 22 participated in the PK substudy. Baseline characteristics between the main and PK participants were comparable, with an average BMI of 25.8 kg/m2 (SD 4.3). In the PK substudy, all three rings showed similar NES PK: mean area under the curve (AUC(0-72)) 34,181 pg*day/mL; concentration maximum (Cmax) 918 pg/mL; time to maximum concentration (Tmax) 3.5 h. For E2, the Cmax occurred at 2 h, and was significantly higher with the 20 mcg/day ring (mean 390 pg/mL); 10 mcg/day, 189 pg/mL, p=.003; 40 mcg/day, 189 pg/mL, p<.001), and declined rapidly to≤50 pg/mL for all doses by 24 h. For all subjects, the median E2 levels remained under 35 pg/mL during treatment.

CONCLUSION:

PK parameters of NES were not affected when paired with different doses of E2, but E2 levels from all three doses were lower than anticipated and no dose response was observed.

IMPLICATIONS:

While these novel estradiol-releasing combination contraceptive vaginal rings provided sustained release of contraceptive levels of Nestorone over 90 days, the E2 levels achieved were not consistent with bone protection, and a dose-response was not observed.

KEYWORDS:

Continuous cycling; Contraception; Contraceptive vaginal ring; Estradiol; Nestorone; Pharmacokinetics

PMID:
29409834
PMCID:
PMC5948142
[Available on 2019-05-01]
DOI:
10.1016/j.contraception.2018.01.012

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center